Evidence map›Paper›PMID 11264375›Full record

ArticleJournal of virology2001

Evaluation of interactions of human cytomegalovirus immediate-early IE2 regulatory protein with small ubiquitin-like modifiers and their conjugation enzyme Ubc9.

J H Ahn, Y Xu, W J Jang, M J Matunis, G S Hayward

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 100 citations in OpenAlex.

  1. SUMO modifies GβL and mediates mTOR signaling.The Journal of biological chemistry · 2024
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Viral manipulation of the cellular sumoylation machinery.Cell communication and signaling : CCS · 2017
    Review
  8. Article
  9. Viral Interplay with the Host Sumoylation System.Advances in experimental medicine and biology · 2017
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

J H AhnMolecular Virology Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.
Y Xu
W J Jang
M J Matunis
G S Hayward
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Role of the Granzyme B Pathway in AGAP01HL056091 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BALDWIN, WILLIAM M · 1997 to 2007
$10.9M
Regulation and Function of SUMO Protein Modification -Equipment SupplementR01GM060980 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI MATUNIS, MICHAEL J. · 2000 to 2023
$7.1M
IMMEDIATE-EARLY REGULATORY GENES OF CYTOMEGALOVIRUSR01AI024576 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HAYWARD, GARY S · 1987 to 2007
$2.0M
NHLBI NIH HHS P01 HL056091NHLBI NIH HHS P01 HL56091NIAID NIH HHS R01 AI024576NIAID NIH HHS R01 AI24576NIGMS NIH HHS R01 GM060980
6 · The paper itself

Abstract

The human cytomegalovirus (HCMV) major immediate-early protein IE2 is a nuclear phosphoprotein that is believed to be a key regulator in both lytic and latent infections. Using yeast two-hybrid screening, small ubiquitin-like modifiers (SUMO-1, SUMO-2, and SUMO-3) and a SUMO-conjugating enzyme (Ubc9) were isolated as IE2-interacting proteins. In vitro binding assays with glutathione S-transferase (GST) fusion proteins provided evidence for direct protein-protein interaction. Mapping data showed that the C-terminal end of SUMO-1 is critical for interaction with IE2 in both yeast and in vitro binding assays. IE2 was efficiently modified by SUMO-1 or SUMO-2 in cotransfected cells and in cells infected with a recombinant adenovirus expressing HCMV IE2, although the level of modification was much lower in HCMV-infected cells. Two lysine residues at positions 175 and 180 were mapped as major alternative SUMO-1 conjugation sites in both cotransfected cells and an in vitro sumoylation assay and could be conjugated by SUMO-1 simultaneously. Although mutations of these lysine residues did not interfere with the POD (or ND10) targeting of IE2, overexpression of SUMO-1 enhanced IE2-mediated transactivation in a promoter-dependent manner in reporter assays. Interestingly, many other cellular proteins identified as IE2 interaction partners in yeast two-hybrid assays also interact with SUMO-1, suggesting that either directly bound or covalently conjugated SUMO moieties may act as a bridge for interactions between IE2 and other SUMO-1-modified or SUMO-1-interacting proteins. When we investigated the intracellular localization of SUMO-1 in HCMV-infected cells, the pattern changed from nuclear punctate to predominantly nuclear diffuse in an IE1-dependent manner at very early times after infection, but with some SUMO-1 protein now associated with IE2 punctate domains. However, at late times after infection, SUMO-1 was predominantly detected within viral DNA replication compartments containing IE2. Taken together, these results show that HCMV infection causes the redistribution of SUMO-1 and that IE2 both physically binds to and is covalently modified by SUMO moieties, suggesting possible modulation of both the function of SUMO-1 and protein-protein interactions of IE2 during HCMV infection.

Indexed as

Membrane GlycoproteinsSmall Ubiquitin-Related Modifier ProteinsTrans-ActivatorsUbiquitin-Conjugating EnzymesViral Envelope ProteinsViral ProteinsAmino Acid SequenceAnimalsBinding SitesB-LymphocytesCell LineCytomegalovirusDNA, ViralHumansImmediate-Early ProteinsLigasesDNA, Viralglycoprotein H, Cytomegalovirusglycoprotein H, Human cytomegalovirusglycoprotein O, cytomegalovirusIE1 protein, cytomegalovirusIE2 protein, CytomegalovirusImmediate-Early ProteinsLigasesMembrane GlycoproteinsSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinSUMO2 protein, humanSUMO3 protein, humanTrans-ActivatorsUbiquitin-Conjugating EnzymesUbiquitin-Conjugating Enzyme UBC9UbiquitinsUL115 protein, Human herpesvirus 5Viral Envelope ProteinsViral Proteins

Identifiers

PMID11264375
PMCPMC114877
OpenAlexW1980447566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.